Span Health is a digital care platform that aims to help people avoid lifestyle-induced diseases, symptoms, medication, and complications. The company has helped more than 10,000 people to live a better and longer life. Span Health's easy-to-use mobile application allows patients to chat with clinicians, order blood tests at home, book video consultations, and see results in the application itself. Moreover, in 2019, the company agreed on a National Health Service (NHS) pilot test for 100 patients in collaboration with the National Institute of Health Research in North West London. Span Health will use the investment to provide employees with blood tests to screen for health risk factors and recover from detected illness safely and sustainably, improve its platform data insights, prediction and machine learning to better structure the clinician's processes, and further reduce its operational costs.
days to go:
Expired
investment:
£134,892
Jupiter Diagnostics provide a patent-protected portable reader and test card to provide reliable and cost-effective blood results. Each test card has the ability to measure multiple tests from a prick of blood from the finger and can deliver laboratory-quality results in just ten minutes.
days to go:
Expired
investment:
£2,005,050
Ecologi is dedicated to motivating and enabling businesses to expedite global climate action. Through Ecologi Zero, their carbon footprinting tool with Xero, customers can calculate emission and establish reduction objectives, while also funding tree planting and high quality carbon avoidance and removal projects.
They can share their impact dashboard encourage and inspiring others, and all of this is made possible through monthly Climate Action subscriptions, PAYG Impact shop, and Ecommerce API.
days to go:
Expired
investment:
£549,363
Carocell Bio is an early-stage Research and Design (R&D) company aiming to develop nanoparticle-based, novel peptide anti-inflammatories to treat atopic dermatitis/eczema (AD) and other serious inflammatory diseases. It argues that millions of people continue to be affected by debilitating skin ailments, which in turn, escalates the development of new pharmaceutical drugs. The company asserts that the anti-inflammatory therapeutics market will reach US$122.6 billion by 2025 from US$95.9 billion in 2019. The company aims to be a major contender in this market. Carocell Bio has also been awarded an Innovate UK grant of £390,874. The company is seeking £1 million in equity investment over the next 12 months to show that their compounds work in human tissue biopsies of several inflammatory diseases.
days to go:
Expired
investment:
Withheld
Molecular Warehouse are trying to create a world where most diseases are prevented by giving people the chance to monitor and manage their helath where ever and whenever. Molecular Warehouse have developed a platform that allows anyone to test themselves at any time.
days to go:
Expired
investment:
£737,480
Central Plains Group (CPG) is a farming company with a vision to build an integrated zero-waste farming and processing operation to supply the rapidly expanding starch, bioplastics and plant protein markets globally. It aims to be a contender in the aforementioned markets that are expected to be worth more than $30 billion by 2026. CPG previously built and ran a large-scale farming operation in Eastern Europe for over 25 years, over 200,000 hectares of land and earning more than $250 million in profits. It aspires to take things further by promoting sustainable farming and contributing to the zero-waste bio-economy. CPG established its core feedstock farming platform in Ukraine achieving over £3 million worth of revenue with a net profit of £300,000 having supplied 11,000 tonnes of crisping potatoes to Pepsico and Ukraine Supermarkets. CPG will use the investment to actualise the construction of a 15 tonne/hour starch production facility powered by a green energy source.
days to go:
Expired
investment:
£3,031,685
Emission Solutions (EMSOL) empowers organisations to take everyday steps to reduce emissions through their real-time emission monitoring and analytics system. EMSOL's open framework platform is built with networks of sensors like air and noise pollution, vehicle tracking, and working with any asset tags and emission sensors which enables EMSOL to perform real-time measurements with location tags and calibrated sensors. Data from these platforms are easily shared on dashboards, through notifications and gives detailed real-time data on urban noise, air quality, and vehicle pollution. To date, EMSOL won Rushlight Environmental Analysis Award, achieve yearly income targets, rated 5th place in the national PowerUp Index and 4th in the London and South East region. Moreover, EMSOL also won a fully funded project sponsored by DFT to deploy EMSOL technology into the rail sector. The company will use the funds to expand its customer base and increase the number of deployment sites.
days to go:
Expired
investment:
£316,884
Ablatus Therapeutics is a MedTech company developing a one-of-a-kind tissue ablation platform known as Bimodal Electric Tissue Ablation (BETA). This technology has been designed to overcome the limitations of existing products by offering ablation solutions in oncology (tumours) as well as non-oncology targets. With the proceeds, the company will finish the final elements of engineering of the generator and probe. It will also deliver formal safety test data that is a prerequisite for subsequent clinical trials.
days to go:
Expired
investment:
Withheld
International Ambulances (IA) aims to save lives and to provide better outcomes for patients, paramedics and hospitals. The company is building a revolutionary ambulance the 'ACESO' that will be the first ever purpose built global ambulance. ACESO will address known challenges of accident & emergency departments and promote the NHS 'See and Treat' strategy. Of the ambulance fleet size of 14,000, International Ambulances (IA) has identified about 1,200 A&E Ambulances of which the opportunity for ACESO is 500 per year.
days to go:
Expired
investment:
£251,600
